Abstract:The voltage-gated calcium channels CaV3.1-3.3 constitute the T-type subfamily, whose dysfunctions are associated with epilepsy, psychiatric disorders, and chronic pain. The unique properties of low-voltage-activation, faster inactivation, and slower deactivation of these channels support their role in modulation of cellular excitability and low-threshold firing. Thus, selective T-type calcium channel antagonists are highly sought after. Here, we explored Ugi-azide multicomponent reaction products to identify compounds targeting T-type calcium channel. Of the 46 compounds tested, an analog of benzimidazolonepiperidine-5bk (1-{1-[(R)-{1-[(1S)-1-phenylethyl]-1H-1,2,3,4-tetrazol-5-yl}(thiophen-3-yl)methyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one) modulated depolarization-induced calcium influx in rat sensory neurons. Modulation of T-type calcium channels by 5bk was further confirmed in whole-cell patch clamp assays in dorsal root ganglion (DRG) neurons, where pharmacological isolation of T-type currents led to a time- and concentration-dependent regulation with a low micromolar IC50. Lack of an acute effect of 5bk argues against a direct action on T-type channels. Genetic knockdown revealed CaV3.2 to be the isoform preferentially modulated by 5bk. High voltage-gated calcium, as well as tetrodotoxin-sensitive and -resistant sodium, channels were unaffected by 5bk. 5bk inhibited spontaneous excitatory postsynaptic currents and depolarization-evoked release of calcitonin gene-related peptide from lumbar spinal cord slices. Notably, 5bk did not bind human mu, delta, or kappa opioid receptors. 5bk reversed mechanical allodynia in rat models of HIV-associated neuropathy, chemotherapy-induced peripheral neuropathy, and spinal nerve ligation-induced neuropathy, without effects on locomotion or anxiety. Thus, 5bk represents a novel T-type modulator that could be used to develop nonaddictive pain therapeutics.

Structural basis for inhibition of the lysosomal two-pore channel TPC2 by a small molecule antagonist

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

Descending to inhibit: Antagonist-induced downward shift of VSD II in TPC2

A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.

Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal function

Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore

Bidirectional Allosteric Coupling between PIP2 Binding and the Pore of the Oncochannel TRPV6

Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors

Molecular and structural basis of the dual regulation of the polycystin-2 ion channel by small-molecule ligands

The mechanism and energetics of a ligand-controlled hydrophobic gate in a mammalian two pore channel

Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2

Structural Pharmacology of TRPV4 Antagonists

Structural basis for human Ca v 3.2 inhibition by selective antagonists

Identification of a drug binding pocket in TMEM16F calcium-activated ion channel and lipid scramblase

Identification of Novel P2X7R Antagonists by Using Structure‐based Virtual Screening and Cell‐based Assays

Structural Basis of TRPV3 Inhibition by an Antagonist.

The Inhibition Mechanism of the SUR2A-containing KATP Channel by a Regulatory Helix

Structural basis of inhibition of human NaV1.8 by the tarantula venom peptide Protoxin-I

Regulation and drug modulation of a voltage-gated sodium channel: Pivotal role of the S4–S5 linker in activation and slow inactivation

Molecular Basis for Pore Blockade of Human Na+ Channel Nav1.2 by the Μ-Conotoxin KIIIA.

Structure and inhibition mechanisms of essential transporter efflux protein A